IDEXX Laboratories (LTS:0J8P) Cyclically Adjusted Revenue per Share: $40.97 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0J8P IDEXX Laboratories Inc LTS:0J8P
95 GF Score
Price $556.09
GF Value $632.73
Valuation Modestly Undervalued
View Full Analysis

What is IDEXX Laboratories Cyclically Adjusted Revenue per Share?

IDEXX Laboratories LTS:0J8P -0.61% 95 Cyclically Adjusted Revenue per Share is $40.97 as of Mar. 2026. GuruFocus rates LTS:0J8P with a GF Score™ of 95/100 and a GF Value™ of $632.73 (Modestly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IDEXX Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was $14.231. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $40.97 for the trailing ten years ended in Mar. 2026.

During the past 12 months, IDEXX Laboratories's average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IDEXX Laboratories was 16.30% per year. The lowest was 11.80% per year. And the median was 13.70% per year.

As of today (2026-08-02), IDEXX Laboratories's current stock price is $556.09. IDEXX Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $40.97. IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is 13.57.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


IDEXX Laboratories  (LTS:0J8P) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=556.09/40.97
=13.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IDEXX Laboratories Cyclically Adjusted Revenue per Share Related Terms


IDEXX Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Cyclically Adjusted Revenue per Share Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.51 28.22 32.11 35.88 39.96

IDEXX Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.56 37.77 38.51 39.96 40.97

LTS:0J8P vs A, NTRA, WAT: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PS Ratio falls into.


LTS:0J8P
95GF Score
IDEXX Laboratories Inc LTS:0J8P
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IDEXX Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.231/330.2130*330.2130
=14.231

Current CPI (Mar. 2026) = 330.2130.

IDEXX Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.137 241.018 7.038
201609 4.919 241.428 6.728
201612 4.887 241.432 6.684
201703 5.134 243.801 6.954
201706 5.663 244.955 7.634
201709 5.512 246.819 7.374
201712 5.683 246.524 7.612
201803 6.045 249.554 7.999
201806 6.555 251.989 8.590
201809 6.167 252.439 8.067
201812 6.256 251.233 8.223
201903 6.580 254.202 8.548
201906 7.078 256.143 9.125
201909 6.905 256.759 8.880
201912 6.938 256.974 8.915
202003 7.224 258.115 9.242
202006 7.379 257.797 9.452
202009 8.326 260.280 10.563
202012 8.288 260.474 10.507
202103 8.948 264.877 11.155
202106 9.534 271.696 11.587
202109 9.368 274.310 11.277
202112 9.299 278.802 11.014
202203 9.777 287.504 11.229
202206 10.141 296.311 11.301
202209 10.006 296.808 11.132
202212 9.884 296.797 10.997
202303 10.722 301.836 11.730
202306 11.236 305.109 12.160
202309 10.900 307.789 11.694
202312 10.741 306.746 11.563
202403 11.483 312.332 12.140
202406 12.034 314.175 12.648
202409 11.746 315.301 12.302
202412 11.560 315.605 12.095
202503 12.188 319.799 12.585
202506 13.698 322.561 14.023
202509 13.700 324.800 13.928
202512 13.551 324.054 13.809
202603 14.231 330.213 14.231

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $40.97 mean?
IDEXX Laboratories (LTS:0J8P) has a Cyclically Adjusted Revenue per Share of $40.97 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Cyclically Adjusted Revenue per Share too high?
IDEXX Laboratories' current Cyclically Adjusted Revenue per Share is $40.97. Overall, IDEXX Laboratories has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted Revenue per Share compare to A and NTRA?
IDEXX Laboratories' Cyclically Adjusted Revenue per Share of $40.97 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Cyclically Adjusted Revenue per Share is $40.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (LTS:0J8P) is currently considered Modestly Undervalued. The stock's GF Value™ is $632.73, compared to a current price of $556.09 — trading 12.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $40.97. IDEXX Laboratories' overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For IDEXX Laboratories (LTS:0J8P), the current Cyclically Adjusted Revenue per Share is $40.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (LTS:0J8P) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of $556.09 is trading 12.1% below its estimated GF Value™ of $632.73. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for LTS:0J8P:

  • Cyclically Adjusted Revenue per Share: $40.97
  • GF Value™: $632.73 vs. price of $556.09 (12.1% below fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the LTS:0J8P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
95GF Score

Get the complete analysis for LTS:0J8P

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$556.09
Price
$632.73
GF Value